Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 582

Results For "IT"

10513 News Found

IOL Chemicals and Pharmaceuticals posts Q4 FY25 PAT at Rs. 31.42 Cr
News | May 17, 2025

IOL Chemicals and Pharmaceuticals posts Q4 FY25 PAT at Rs. 31.42 Cr

IOL Chemicals and Pharmaceuticals has posted net profit of Rs.101.07 crores for the Financial Year ended March 31, 2025


Jubilant Pharmova posts Q4 FY25 consolidated PAT at Rs. 153.6 Cr
News | May 17, 2025

Jubilant Pharmova posts Q4 FY25 consolidated PAT at Rs. 153.6 Cr

Jubilant Pharmova has posted net profit of Rs. 839.4 crores for the Financial Year ended March 31, 2025


JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25
News | May 16, 2025

JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25

Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25


Shelter Pharma launches three new products
News | May 16, 2025

Shelter Pharma launches three new products

Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India


Remedium Lifecare secures Rs. 182.7 crore export deal
News | May 16, 2025

Remedium Lifecare secures Rs. 182.7 crore export deal

The CDMO upgrade represents a transformational step for Remedium Lifecare


Emcutix launches urea-based skin-care moisturizers ‘Ureaderm'
News | May 14, 2025

Emcutix launches urea-based skin-care moisturizers ‘Ureaderm'

Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration


Bayer confirms 2025 targets after solid start to the year
News | May 14, 2025

Bayer confirms 2025 targets after solid start to the year

EBITDA before special items decreases to €4.08 billion (7.4%)


Caplin Steriles gets USFDA approval for Haloperidol Decanoate Injection
Drug Approval | May 14, 2025

Caplin Steriles gets USFDA approval for Haloperidol Decanoate Injection

Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy


Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr
News | May 14, 2025

Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr

For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.